A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

David Siegel,Niels W.C.J. van de Donk,Pieter Sonneveld,Craig C. Hofmeister,Nizar J. Bahlis,Ruben Niesvizky,Lars Sternas,Teresa Peluso,Sheetal Shah,Ana Slaughter,Mohamed H. Zaki,Jianming Wang,Jesús F. San Miguel

A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

2016

David Siegel
Niels W.C.J. van de Donk
Pieter Sonneveld
Craig C. Hofmeister
Nizar J. Bahlis
Ruben Niesvizky
Lars Sternas
Teresa Peluso
Sheetal Shah
Ana Slaughter
Mohamed H. Zaki
Jianming Wang
Jesús F. San Miguel

TPS8072Background: Multiple myeloma (MM) plasma cells express programmed cell death ligand 1 (PD-L1). In preclinical studies, monoclonal antibodies (mAbs) directed against PD-L1 demonstrated antimy...

Keywords:

Refractory Multiple Myeloma
Dexamethasone
Pomalidomide
Oncology
Pathology
Durvalumab
Internal medicine
Medicine
low dose
Cancer research
Multiple myeloma
in patient
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations